SNP‑810 is an innovative oral combination analgesic, combining high liver-safety paracetamol with a non-addictive, minimal-respiratory-depression κ-opioid, designed for moderate to severe pain management.
Key advantages include non-controlled therapy, non-lethal hepatotoxicity, non-addictive with high liver safety acetaminophen, no respiratory depression, and patented new ingredient combination. The pivotal clinical trial met its primary endpoint (p<0.0001); no clinically meaningful hepatotoxicity was observed. Products containing the same active ingredients are already authorized in US, Europe and Asia, offering a safer alternative to traditional addictive opioid analgesics.

More details: https://sinewpharma.com/en/products-detail3-6.htm

1. Non-controlled Oral Therapy: Innovative oral formulation not classified as a controlled substance, avoiding regulatory restrictions. Protected by a patent on the new ingredient combination, providing strong regulatory protection and clear market differentiation.

2. Safe and non-hepatotoxic: Incorporates a hepatotoxicity-free acetaminophen, overcoming the liver safety limitations of conventional analgesics. Optimized metabolic pathway design provides a broader safety margin and greater dosing flexibility.

3. Innovative Formulation Design: Combines hepatotoxicity-free acetaminophen with a non-addictive κ-opioid analgesic. Specifically developed for moderate-to-severe pain management without reliance on controlled narcotics.

4. Clinically Advanced with Proven Results: Pivotal clinical trial completed enrollment in knee replacement patients. Clinical data demonstrated favorable safety and analgesic efficacy, supporting further development and commercialization potential.

5. Non-addictive and no respiratory depression: Features a non-addictive mechanism of action, ensuring long-term safety without risks of dependency and respiratory depression, serving as a safer alternative to traditional μ-opioid analgesics.

On top of these main advantages, the product serves to addresses the global opioid misuse and dependency crisis, improving the quality of postoperative and chronic pain management.